This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lundqvist, A. Articles by Childs, R. Search for Related Content PubMed PubMed Citation Articles by Lundqvist, A. Articles by Childs, R.

Bortezomib and Depsipeptide Sensitize Tumors to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand: A Novel Method to Potentiate Natural Killer Cell Tumor Cytotoxicity

¹ Hematology Branch, National Heart, Lung, and Blood Institute, ² Laboratory of Tumor Immunology and Biology, and ³ Thoracic Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Richard Childs, Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892-1652, Room 3-5140, Building 10-CRC, 10 Center Drive MSC 1202, Bethesda, MD 20892-1202. Phone: 301-594-8002; Fax: 301-480-2664; E-mail: childsr{at}nih.nhlbi.gov.

The proteasome inhibitor, bortezomib, and the histone deacetylase inhibitor, depsipeptide (FK228), up-regulate tumor death receptors. Therefore, we investigated whether pretreatment of malignant cells with these agents would potentiate natural killer (NK)–mediated tumor killing. NK cells isolated from healthy donors and patients with cancer were expanded in vitro and then tested for cytotoxicity against tumor cell lines before and after exposure to bortezomib or depsipeptide. In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, exposure to these drugs significantly increased NK cell–mediated tumor lysis compared with untreated tumor controls (P < 0.001). Furthermore, NK cells expanded from patients with metastatic renal cell carcinoma were significantly more cytotoxic against autologous tumor cells when pretreated with either bortezomib or depsipeptide compared with untreated tumors. Tumors sensitized to NK cell cytotoxicity showed a significant increase in surface expression of DR5 [tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)-R2; P < 0.05]; in contrast, surface expression of MHC class I, MIC-A/B, DR4 (TRAIL-R1), and Fas (CD95) did not change. The enhanced susceptibility to NK cell killing was completely abolished by blocking TRAIL on NK cells, and partially abolished by blocking DR5 on tumor cells. These findings show that drug-induced sensitization to TRAIL could be used as a novel strategy to potentiate the anticancer effects of adoptively infused NK cells in patients with cancer. (Cancer Res 2006; 66(14): 7317-25)

This article has been cited by other articles:

				M. C. Crisanti, A. F. Wallace, V. Kapoor, F. Vandermeers, M. L. Dowling, L. P. Pereira, K. Coleman, B. G. Campling, Z. G. Fridlender, G. D. Kao, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer Mol. Cancer Ther., August 1, 2009; 8(8): 2221 - 2231. [Abstract] [Full Text] [PDF]

				D. S. Schrump Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications Clin. Cancer Res., June 15, 2009; 15(12): 3947 - 3957. [Abstract] [Full Text] [PDF]

				H. R. Salih and A. Steinle Reinforcing natural killers Blood, June 11, 2009; 113(24): 6042 - 6043. [Full Text] [PDF]

				A. Lundqvist, H. Yokoyama, A. Smith, M. Berg, and R. Childs Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells Blood, June 11, 2009; 113(24): 6120 - 6127. [Abstract] [Full Text] [PDF]

				K.-F. Chen, P.-Y. Yeh, C. Hsu, C.-H. Hsu, Y.-S. Lu, H.-P. Hsieh, P.-J. Chen, and A.-L. Cheng Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway J. Biol. Chem., April 24, 2009; 284(17): 11121 - 11133. [Abstract] [Full Text] [PDF]

				X. Wang, A. Ottosson, C. Ji, X. Feng, M. Nordenskjold, J.-I. Henter, B. Fadeel, and C. Zheng Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity Haematologica, April 1, 2009; 94(4): 470 - 478. [Abstract] [Full Text] [PDF]

				A. S. M. Yong, K. Keyvanfar, N. Hensel, R. Eniafe, B. N. Savani, M. Berg, A. Lundqvist, S. Adams, E. M. Sloand, J. M. Goldman, et al. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib Blood, January 22, 2009; 113(4): 875 - 882. [Abstract] [Full Text] [PDF]

				S. Armeanu, M. Krusch, K. M. Baltz, T. S. Weiss, I. Smirnow, A. Steinle, U. M. Lauer, M. Bitzer, and H. R. Salih Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma Clin. Cancer Res., June 1, 2008; 14(11): 3520 - 3528. [Abstract] [Full Text] [PDF]

				M. Vales-Gomez, S. E. Chisholm, R. L. Cassady-Cain, P. Roda-Navarro, and H. T. Reyburn Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors Cancer Res., March 1, 2008; 68(5): 1546 - 1554. [Abstract] [Full Text] [PDF]

				F.-T. Liu, S. G. Agrawal, J. G. Gribben, H. Ye, M.-Q. Du, A. C. Newland, and L. Jia Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL Blood, March 1, 2008; 111(5): 2797 - 2805. [Abstract] [Full Text] [PDF]

				J. Shi, G. J. Tricot, T. K. Garg, P. A. Malaviarachchi, S. M. Szmania, R. E. Kellum, B. Storrie, A. Mulder, J. D. Shaughnessy Jr, B. Barlogie, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma Blood, February 1, 2008; 111(3): 1309 - 1317. [Abstract] [Full Text] [PDF]

				W. H.D. Hallett, E. Ames, M. Motarjemi, I. Barao, A. Shanker, D. L. Tamang, T. J. Sayers, D. Hudig, and W. J. Murphy Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition J. Immunol., January 1, 2008; 180(1): 163 - 170. [Abstract] [Full Text] [PDF]

				D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, E. Kruchin, et al. Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin Clin. Cancer Res., January 1, 2008; 14(1): 188 - 198. [Abstract] [Full Text] [PDF]